Prophage

Type: Keyphrase

Name: Prophage

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Agenus' Annual Shareholder Meeting (Transcript)

5:00 PM ETOperatorGood day ladies and gentlemen and welcome to the Agenus Annual Shareholders Meeting Conference Call. As a reminder, today’s conference is being recorded. At this time, I’d like to turn the conference over to Ms. Karen Valentine please ... [Published Seeking Alpha - Jun 13 2013]

Entities: Agenus Inc, Prophage, QS-21 Stimulon

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Enterococcus faecalis Prophage Dynamics and Contributions to Pathogenic Traits

by Renata C. Matos, Nicolas Lapaque, Lionel Rigottier-Gois, Laurent Debarbieux, Thierry Meylheuc, Bruno Gonzalez-Zorn, Francis Repoila, Maria de Fatima Lopes, Pascale SerrorPolylysogeny is frequently considered to be the result of an adaptive evolutionary ... [Published Bionity.com - Jun 12 2013]

Entities: Enterococcus faecalis, Prophage, Pathogenic

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Agenus Inc

Agenus initiates enrollment in Phase II glioblastoma multiforme study

Agenus Inc., a biotechnology company, has initiated enrollment for a large, randomized Phase II study of Prophage G-200 vaccine in combination with bevacizumab, or Avastin, for treatment of recurrent glioblastoma multiforme, or GBM, in adult patients. ... [Published Individual.com - May 31 2013]

Entities: Agenus Inc, bevacizumab, glioblastoma multiforme

First reported May 22 2013 - Updated May 22 2013 - 3 reports

Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine GlobeNewswire

(GLOBE NEWSWIRE) -- Agenus Inc. (AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with bevacizumab (Avastin(R)) for treatment ... [Published Yahoo! Finance - May 22 2013]

Entities: Prophage, Agenus Inc, Vaccine, bevacizumab

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting

Phase 2 HSPPC-96 Data in Newly Diagnosed GBM PatientsThe single-arm, Phase 2 trial of HSPPC-96 in patients with newly diagnosed GBM included a total of 46 patients treated at eight centers across the United States. Patients were treated with radiation ... [Published Stockwatch - May 01 2013]

Entities: Agenus Inc, temozolomide, glioblastoma, Prophage

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Quickly Approaching Biopharma Catalyst Events

By Scott Matusow : Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 24 2013]

Entities: Prophage, Catalyst, glioma

First reported Mar 14 2013 - Updated Mar 14 2013 - 1 reports

Agenus to Present at the ROTH Annual Conference

Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon® adjuvant1 is being studied in clinical trials for 17 vaccine indications. They include: Agenus pipeline programs include:Saponin Platform: QS-21 Stimulon®Adjuvant ... [Published Stockwatch - Mar 14 2013]

Entities: Agenus Inc, QS-21 Stimulon, Herpes Simplex Virus-2, Prophage, adjuvant

Quotes

"The initiation of enrollment in this groundbreaking trial to evaluate the efficacy of treatment with HSPPC-96 in conjunction with bevacizumab in recurrent GBM represents a major milestone in efforts to develop effective vaccines for people living with brain tumors. The significant commitment to this trial from the NCI is also a reflection of the rapidly emerging promise of vaccines as potential treatment options for millions of people with different forms of cancer" said Andrew T Parsa, study chair for the trial and newly appointed chair of the Department of Neurological Surgery at Northwestern University

Agenus initiates enrollment in Phase II glioblastoma multiforme study [Published Individual.com - May 31 2013]

Just Released: "Agenus Inc. (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile"

Just Released: "Agenus, Inc. (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" [Published Live-PR.com - May 24 2013]

More Content

sort by: Date \| Relevance
Agenus' Annual Shareholder Meeting (Transcript) [Published Seeking Alpha - Jun 13 2013]
Enterococcus faecalis Prophage Dynamics and Con... [Published Bionity.com - Jun 12 2013]
Agenus initiates enrollment in Phase II gliobla... [Published Individual.com - May 31 2013]
Agenus: Near-Term Drivers With A Market Opportu... [Published Seeking Alpha - May 30 2013]
Just Released: "Agenus, Inc. (AGEN) - Pharmaceu... [Published Live-PR.com - May 24 2013]
Agenus Announces Initiation of Enrollment in NC... [Published Yahoo! Finance - May 22 2013]
Agenus Announces Initiation of Enrollment in NC... [Published GlobeNewswire: Acquisitions News - May 22 2013]
Agenus Announces Initiation of Enrollment in NC... [Published Reuters - May 22 2013]
Agenus Announces Initiation of Enrollment in NC... [Published Morningstar.com - May 22 2013]
Positive Phase 2 Data from Agenus' Brain Cancer... [Published GlobeNewswire: Advertising News - May 01 2013]
Positive Phase 2 Data from Agenus' Brain Cancer... [Published Stockwatch - May 01 2013]
Quickly Approaching Biopharma Catalyst Events [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 24 2013]
Agenus to Present at the ROTH Annual Conference [Published Stockwatch - Mar 14 2013]